Intranasal drug delivery: a novel approach

Chugh, Yashpal; Kapoor, Pragati; Kapoor, Arun

doi:10.1007/s12070-009-0044-2

Cited by 9 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to adjuvants’ intrinsic immunomodulatory properties, their combined administration with an antigen elicits superior and long-lasting immune responses while overcoming natural tolerances of mucosal compartments to antigens administered alone [ 7 , 37 , 38 ]. Indeed, mucosal adjuvants need to overcome the harsh conditions of mucosal tissues (e.g., low pH, continuous mucociliary clearance and local enzymes) and rapidly permeate mucus layers in order to induce efficacious responses and establish immune memory [ 39 , 40 ]. Cholera toxin (CT) is produced by Vibrio cholerae and its combined intranasal administration with an antigen has been shown to elicit potent antigen-specific IgA responses in the URT and T cell-mediated responses in animal models [ 41 , 42 , 43 , 44 , 45 ].…”

Section: Introductionmentioning

confidence: 99%

Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice

et al. 2022

View full text Add to dashboard Cite

Continuous viral evolution of SARS-CoV-2 has resulted in variants capable of immune evasion, vaccine breakthrough infections and increased transmissibility. New vaccines that invoke mucosal immunity may provide a solution to reducing virus transmission. Here, we evaluated the immunogenicity of intranasally administered subunit protein vaccines composed of a stabilized SARS-CoV-2 spike trimer or the receptor binding domain (RBD) adjuvanted with either cholera toxin (CT) or an archaeal lipid mucosal adjuvant (AMVAD). We show robust induction of immunoglobulin (Ig) G and IgA responses in plasma, nasal wash and bronchoalveolar lavage in mice only when adjuvant is used in the vaccine formulation. While the AMVAD adjuvant was more effective at inducing systemic antibodies against the RBD antigen than CT, CT was generally more effective at inducing overall higher IgA and IgG titers against the spike antigen in both systemic and mucosal compartments. Furthermore, vaccination with adjuvanted spike led to superior mucosal IgA responses than with the RBD antigen and produced broadly targeting neutralizing plasma antibodies against ancestral, Delta and Omicron variants in vitro; whereas adjuvanted RBD elicited a narrower antibody response with neutralizing activity only against ancestral and Delta variants. Our study demonstrates that intranasal administration of an adjuvanted protein subunit vaccine in immunologically naïve mice induced both systemic and mucosal neutralizing antibody responses that were most effective at neutralizing SARS-CoV-2 variants when the trimeric spike was used as an antigen compared to RBD.

show abstract

Section: Introductionmentioning

confidence: 99%

Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The drug delivery to the brain is also limited by ATP binding cassette (ABC) drug efflux transporter system present in nose. The application of nanoparticles offers an improvement to nose-to-brain drug delivery since they are able to protect the encapsulated drug from biological and/ or chemical degradation, and extracellular transport by P-gp efflux proteins 5,46 . Despite these advances, the quantity of noseto-brain drug delivery mediated by nanoparticles is still unsatisfactory.…”

Section: Strategies Limitationsmentioning

confidence: 99%

Nanoneurotherapeutics approach intended for direct nose to brain delivery

Shadab

Mustafa

Baboota

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

This review highlights the understanding of several brain diseases and the important pathophysiological mechanisms involved. The review discusses the role of nanotherapeutics in treating brain disorders via nose to brain delivery, the mechanisms of drug absorption across nasal mucosa to the brain, strategies to overcome the blood brain barrier, nanoformulation strategies for enhanced brain targeting via nasal route and neurotoxicity issues of nanoparticles.

show abstract

“…The nasal route of administration offers an attractive alternative to the oral route for drug delivery. Intranasal drugs are transported along the olfactory sensory neurons to yield significant concentrations in the cerebrospinal fluids [4]. Intranasal route is noninvasive and painless, does not require sterility regulations, and is readily administered by the patient.…”

Section: Introductionmentioning

confidence: 99%

Formulation and Evaluation of Chitosan-Chondroitin Sulphate Based Nasal Inserts for Zolmitriptan

Κaur

Kaur

2013

BioMed Research International

View full text Add to dashboard Cite

Bioadhesive nasal dosage forms are an attractive method for overcoming rapid mucociliary clearance transport in the nose and for delivering the drug directly to brain. The present study was designed to formulate chondroitin sulphate (CS) and chitosan (CH) nasal inserts employing zolmitriptan, an antimigraine drug. The interpolymer complexes (IPC) formed between –COO− and –OSO3 − groups of CS and –NH3 + group of CH were characterized by infrared spectroscopy (IR), differential scanning analysis (DSC), and zeta potential studies. The unloaded and loaded nasal inserts were evaluated for water uptake studies, and bioadhesive strength studies, scanning electron microscopic studies (SEM). The in vitro drug release and in situ permeation studies were carried out on loaded nasal inserts. The DSC and IR studies confirmed the formation of a complex between the two polymers. The results indicated that the formulation F1 (CH : CS; 30 : 70) was demonstrating the highest bioadhesive strength and zeta potential. The presence of porous structure in the nasal inserts was confirmed by the SEM analysis. Further, in vitro and in situ release studies demonstrated that formulations F9 and F11 (drug : polymer; 1 : 10) were releasing 90% and 98% zolmitriptan over a period of 8 h. It can be concluded that nasal inserts formulated from chitosan-chondroitin sulphate (CH-CS) interpolymer complex (IPC) can be used for delivery of antimigraine drug to brain.

show abstract

Intranasal drug delivery: a novel approach

Cited by 9 publications

References 13 publications

Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice

Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice

Nanoneurotherapeutics approach intended for direct nose to brain delivery

Formulation and Evaluation of Chitosan-Chondroitin Sulphate Based Nasal Inserts for Zolmitriptan

Contact Info

Product

Resources

About